五年持续获益!玛伐凯泰最长随访数据公布,进一步证实在oHCM中的长期疗效与安全性

美通社
Aug 30

百时美施贵宝在2026年欧洲心脏病学会(ESC)年会上公布最长达五年的随访数据,进一步证实 迈凡妥®(玛伐凯泰)在有症状的梗阻性肥厚型心肌病(oHCM)中的长期疗效和安全性 新公布的单臂、开放标签研究数据进一步丰富了玛伐凯泰持续临床获益和良好安全性的证据体系,为心肌肌球蛋白抑制剂(CMI)治疗有症状的oHCM提供了目前随访时间最长的临床开发经验 在欧洲心脏病学会(ESC)年会上公布的其他研究结果,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10